摘要
哺乳动物羧酸酯酶是一种关键的丝氨酸水解酶,在相应的羧酸和醇中催化多种酯类化合物的水解。在人体中的两种主要羧基酯酶,CES 1和CES 2,在过去的十年中已经被确认并得到了很好的研究。CES 1抑制剂在治疗高甘油三酯血症、肥胖和2型糖尿病方面具有潜在的应用价值。由于该酶在胆固醇酯代谢中起着重要的作用。CES 2在包括抗癌药物卡培他滨在内的许多前体药物的代谢激活过程中起着至关重要的作用。还有CPT-11,与CES 2抑制剂合用可改善CPT-11相关的危及生命的腹泻,或提高CES 2底物药物的半衰期。羧酸酯酶的重要作用内源性和异生物代谢的S都引起了人们对针对这些酶的强效和选择性抑制剂的发现和开发的极大兴趣。本文着重对羧酸酯酶抑制剂的应用潜力和近期最新研究的进展进行了综述。多种羧酸酯酶抑制剂的抑制能力及抑制机制综述了丁二胺的合成、半合成和天然化合物。此外,还分析了不同类型CES 1 a的主要结构特征和结构活动关系(Sars)。讨论了NDCES 2抑制剂。本文所总结的所有信息和知识将有助于药化学家设计和开发更有效、更高选择性的羧基化合物。潜在生物医学用途的酯酶抑制剂。
关键词: 羧酯酶,CES 1,CES 2,抑制剂,结构-活性关系(SARS),水解酶。
Current Medicinal Chemistry
Title:Carboxylesterase Inhibitors: An Update
Volume: 25 Issue: 14
关键词: 羧酯酶,CES 1,CES 2,抑制剂,结构-活性关系(SARS),水解酶。
摘要: Mammalian carboxylesterases are key serine hydrolases that catalyze the hydrolysis of a wide variety of ester compounds in the corresponding carboxylic acids and alcohols. In human, two major carboxylesterases, CES1 and CES2, have been identified and well-studied over the past decade. CES1 inhibitors have potential applications in the treatment of hypertriglyceridaemia, obesity and type 2 diabetes, owing to that this enzyme plays prominent role in the metabolism of cholesteryl esters. CES2 plays crucial roles in the metabolic activation of many prodrugs including anticancer agents capecitabine and CPT-11. Co-administration with CES2 inhibitors may ameliorate CPT-11 associated lifethreatening diarrhea or improve the half-lives of CES2-substrate drugs. The important roles of carboxylesterases in both endogenous and xenobiotic metabolism arouse great interest in the discovery and development of potent and selective inhibitors against these enzymes. This review is focused on the application potentials and recent advances in the discovery and development of carboxylesterases inhibitors. The inhibitory capacities and inhibition mechanism of a variety of carboxylesterases inhibitors including synthetic, semi-synthetic and natural compounds are comprehensively summarized. Furthermore, the key structural features and structure-activity relationships (SARs) of different classes of CES1 and CES2 inhibitors are discussed. All information and knowledge summarized in this review will be very helpful for the medicinal chemists to design and develop more potent and highly selective carboxylesterases inhibitors for potential biomedical applications.
Export Options
About this article
Cite this article as:
Carboxylesterase Inhibitors: An Update, Current Medicinal Chemistry 2018; 25 (14) . https://dx.doi.org/10.2174/0929867325666171204155558
DOI https://dx.doi.org/10.2174/0929867325666171204155558 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements